Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 32

1.

A NOTCH feed-forward loop drives reprogramming from adrenergic to mesenchymal state in neuroblastoma.

van Groningen T, Akogul N, Westerhout EM, Chan A, Hasselt NE, Zwijnenburg DA, Broekmans M, Stroeken P, Haneveld F, Hooijer GKJ, Savci-Heijink CD, Lakeman A, Volckmann R, van Sluis P, Valentijn LJ, Koster J, Versteeg R, van Nes J.

Nat Commun. 2019 Apr 4;10(1):1530. doi: 10.1038/s41467-019-09470-w.

2.

Neuroblastoma is composed of two super-enhancer-associated differentiation states.

van Groningen T, Koster J, Valentijn LJ, Zwijnenburg DA, Akogul N, Hasselt NE, Broekmans M, Haneveld F, Nowakowska NE, Bras J, van Noesel CJM, Jongejan A, van Kampen AH, Koster L, Baas F, van Dijk-Kerkhoven L, Huizer-Smit M, Lecca MC, Chan A, Lakeman A, Molenaar P, Volckmann R, Westerhout EM, Hamdi M, van Sluis PG, Ebus ME, Molenaar JJ, Tytgat GA, Westerman BA, van Nes J, Versteeg R.

Nat Genet. 2017 Aug;49(8):1261-1266. doi: 10.1038/ng.3899. Epub 2017 Jun 26.

PMID:
28650485
3.

Protein arginine methyltransferase 1 is a novel regulator of MYCN in neuroblastoma.

Eberhardt A, Hansen JN, Koster J, Lotta LT Jr, Wang S, Livingstone E, Qian K, Valentijn LJ, Zheng YG, Schor NF, Li X.

Oncotarget. 2016 Sep 27;7(39):63629-63639. doi: 10.18632/oncotarget.11556.

4.

TERT rearrangements are frequent in neuroblastoma and identify aggressive tumors.

Valentijn LJ, Koster J, Zwijnenburg DA, Hasselt NE, van Sluis P, Volckmann R, van Noesel MM, George RE, Tytgat GA, Molenaar JJ, Versteeg R.

Nat Genet. 2015 Dec;47(12):1411-4. doi: 10.1038/ng.3438. Epub 2015 Nov 2.

PMID:
26523776
5.

Ataxia-telangiectasia mutated (ATM) silencing promotes neuroblastoma progression through a MYCN independent mechanism.

Mandriota SJ, Valentijn LJ, Lesne L, Betts DR, Marino D, Boudal-Khoshbeen M, London WB, Rougemont AL, Attiyeh EF, Maris JM, Hogarty MD, Koster J, Molenaar JJ, Versteeg R, Ansari M, Gumy-Pause F.

Oncotarget. 2015 Jul 30;6(21):18558-76.

6.

Functional MYCN signature predicts outcome of neuroblastoma irrespective of MYCN amplification.

Valentijn LJ, Koster J, Haneveld F, Aissa RA, van Sluis P, Broekmans ME, Molenaar JJ, van Nes J, Versteeg R.

Proc Natl Acad Sci U S A. 2012 Nov 20;109(47):19190-5. doi: 10.1073/pnas.1208215109. Epub 2012 Oct 22.

7.

LIN28B induces neuroblastoma and enhances MYCN levels via let-7 suppression.

Molenaar JJ, Domingo-Fernández R, Ebus ME, Lindner S, Koster J, Drabek K, Mestdagh P, van Sluis P, Valentijn LJ, van Nes J, Broekmans M, Haneveld F, Volckmann R, Bray I, Heukamp L, Sprüssel A, Thor T, Kieckbusch K, Klein-Hitpass L, Fischer M, Vandesompele J, Schramm A, van Noesel MM, Varesio L, Speleman F, Eggert A, Stallings RL, Caron HN, Versteeg R, Schulte JH.

Nat Genet. 2012 Nov;44(11):1199-206. doi: 10.1038/ng.2436. Epub 2012 Oct 7.

PMID:
23042116
8.

Sequencing of neuroblastoma identifies chromothripsis and defects in neuritogenesis genes.

Molenaar JJ, Koster J, Zwijnenburg DA, van Sluis P, Valentijn LJ, van der Ploeg I, Hamdi M, van Nes J, Westerman BA, van Arkel J, Ebus ME, Haneveld F, Lakeman A, Schild L, Molenaar P, Stroeken P, van Noesel MM, Ora I, Santo EE, Caron HN, Westerhout EM, Versteeg R.

Nature. 2012 Feb 22;483(7391):589-93. doi: 10.1038/nature10910.

PMID:
22367537
9.

Antitumor activity of sustained N-myc reduction in rhabdomyosarcomas and transcriptional block by antigene therapy.

Tonelli R, McIntyre A, Camerin C, Walters ZS, Di Leo K, Selfe J, Purgato S, Missiaglia E, Tortori A, Renshaw J, Astolfi A, Taylor KR, Serravalle S, Bishop R, Nanni C, Valentijn LJ, Faccini A, Leuschner I, Formica S, Reis-Filho JS, Ambrosini V, Thway K, Franzoni M, Summersgill B, Marchelli R, Hrelia P, Cantelli-Forti G, Fanti S, Corradini R, Pession A, Shipley J.

Clin Cancer Res. 2012 Feb 1;18(3):796-807. doi: 10.1158/1078-0432.CCR-11-1981. Epub 2011 Nov 7.

10.

Inactivation of CDK2 is synthetically lethal to MYCN over-expressing cancer cells.

Molenaar JJ, Ebus ME, Geerts D, Koster J, Lamers F, Valentijn LJ, Westerhout EM, Versteeg R, Caron HN.

Proc Natl Acad Sci U S A. 2009 Aug 4;106(31):12968-73. doi: 10.1073/pnas.0901418106. Epub 2009 Jun 12.

11.

Dickkopf-3 expression is a marker for neuroblastic tumor maturation and is down-regulated by MYCN.

Koppen A, Ait-Aissa R, Koster J, Øra I, Bras J, van Sluis PG, Caron H, Versteeg R, Valentijn LJ.

Int J Cancer. 2008 Apr 1;122(7):1455-64.

12.

Direct regulation of the minichromosome maintenance complex by MYCN in neuroblastoma.

Koppen A, Ait-Aissa R, Koster J, van Sluis PG, Ora I, Caron HN, Volckmann R, Versteeg R, Valentijn LJ.

Eur J Cancer. 2007 Nov;43(16):2413-22. Epub 2007 Sep 10.

PMID:
17826980
13.

Dickkopf-1 is down-regulated by MYCN and inhibits neuroblastoma cell proliferation.

Koppen A, Ait-Aissa R, Hopman S, Koster J, Haneveld F, Versteeg R, Valentijn LJ.

Cancer Lett. 2007 Oct 28;256(2):218-28. Epub 2007 Jul 23.

PMID:
17643814
14.

Read-through transcript from NM23-H1 into the neighboring NM23-H2 gene encodes a novel protein, NM23-LV.

Valentijn LJ, Koster J, Versteeg R.

Genomics. 2006 Apr;87(4):483-9. Epub 2006 Jan 25.

15.

Inhibition of a new differentiation pathway in neuroblastoma by copy number defects of N-myc, Cdc42, and nm23 genes.

Valentijn LJ, Koppen A, van Asperen R, Root HA, Haneveld F, Versteeg R.

Cancer Res. 2005 Apr 15;65(8):3136-45.

16.

Full transcriptome analysis of rhabdomyosarcoma, normal, and fetal skeletal muscle: statistical comparison of multiple SAGE libraries.

Schaaf GJ, Ruijter JM, van Ruissen F, Zwijnenburg DA, Waaijer R, Valentijn LJ, Benit-Deekman J, van Kampen AH, Baas F, Kool M.

FASEB J. 2005 Mar;19(3):404-6. Epub 2005 Jan 3.

PMID:
15629888
17.

Genetic basis of peripheral neuropathies.

Valentijn LJ, Baas F.

Prog Brain Res. 1998;117:249-64. Review. No abstract available.

PMID:
9932413
18.

Hereditary neuropathy with liability to pressure palsies. Phenotypic differences between patients with the common deletion and a PMP22 frame shift mutation.

Lenssen PP, Gabreëls-Festen AA, Valentijn LJ, Jongen PJ, van Beersum SE, van Engelen BG, van Wensen PJ, Bolhuis PA, Gabreëls FJ, Mariman EC.

Brain. 1998 Aug;121 ( Pt 8):1451-8.

PMID:
9712007
19.

Allelotype of pediatric rhabdomyosarcoma.

Visser M, Sijmons C, Bras J, Arceci RJ, Godfried M, Valentijn LJ, Voûte PA, Baas F.

Oncogene. 1997 Sep;15(11):1309-14.

20.

Caprine homologue of rodent 5'-AMP-activated protein kinase subunit and yeast SNF4/CAT3 is down-regulated by thyroid hormone.

Piosik PA, van Groenigen M, Ponne NJ, Valentijn LJ, Bolhuis PA, Baas F.

Brain Res Mol Brain Res. 1996 Sep 1;40(2):240-53.

PMID:
8872308
21.

Charcot-Marie-Tooth disease type 1A: morphological phenotype of the 17p duplication versus PMP22 point mutations.

Gabreëls-Festen AA, Bolhuis PA, Hoogendijk JE, Valentijn LJ, Eshuis EJ, Gabreëls FJ.

Acta Neuropathol. 1995;90(6):645-9.

PMID:
8615087
22.

Déjérine-Sottas neuropathy is associated with a de novo PMP22 mutation.

Valentijn LJ, Ouvrier RA, van den Bosch NH, Bolhuis PA, Baas F, Nicholson GA.

Hum Mutat. 1995;5(1):76-80.

PMID:
7728152
23.

Prevalence of the 1.5-Mb 17p deletion in families with hereditary neuropathy with liability to pressure palsies.

Mariman EC, Gabreëls-Festen AA, van Beersum SE, Valentijn LJ, Baas F, Bolhuis PA, Jongen PJ, Ropers HH, Gabreëls FJ.

Ann Neurol. 1994 Oct;36(4):650-5.

PMID:
7944298
24.

A frame shift mutation in the PMP22 gene in hereditary neuropathy with liability to pressure palsies.

Nicholson GA, Valentijn LJ, Cherryson AK, Kennerson ML, Bragg TL, DeKroon RM, Ross DA, Pollard JD, McLeod JG, Bolhuis PA, et al.

Nat Genet. 1994 Mar;6(3):263-6. Erratum in: Nat Genet 1994 May;7(1):113.

PMID:
8012388
25.

Alternatively sized duplication in Charcot-Marie-Tooth disease type 1A.

Valentijn LJ, Baas F, Zorn I, Hensels GW, de Visser M, Bolhuis PA.

Hum Mol Genet. 1993 Dec;2(12):2143-6. No abstract available.

PMID:
8111385
26.

Quantitative measurement of duplicated DNA as a diagnostic test for Charcot-Marie-Tooth disease type 1a.

Hensels GW, Janssen EA, Hoogendijk JE, Valentijn LJ, Baas F, Bolhuis PA.

Clin Chem. 1993 Sep;39(9):1845-9.

27.

Deletion of the serine 34 codon from the major peripheral myelin protein P0 gene in Charcot-Marie-Tooth disease type 1B.

Kulkens T, Bolhuis PA, Wolterman RA, Kemp S, te Nijenhuis S, Valentijn LJ, Hensels GW, Jennekens FG, de Visser M, Hoogendijk JE, et al.

Nat Genet. 1993 Sep;5(1):35-9.

PMID:
7693130
28.

Allelic heterogeneity in hereditary motor and sensory neuropathy type Ia (Charcot-Marie-Tooth disease type 1a).

Hoogendijk JE, Janssen EA, Gabreëls-Festen AA, Hensels GW, Joosten EM, Gabreëls FJ, Zorn I, Valentijn LJ, Baas F, Ongerboer de Visser BW, et al.

Neurology. 1993 May;43(5):1010-5.

PMID:
8492918
29.

Identification of a functional initiator sequence in the human MDR1 promoter.

van Groenigen M, Valentijn LJ, Baas F.

Biochim Biophys Acta. 1993 Feb 20;1172(1-2):138-46.

PMID:
8094978
30.

Identical point mutations of PMP-22 in Trembler-J mouse and Charcot-Marie-Tooth disease type 1A.

Valentijn LJ, Baas F, Wolterman RA, Hoogendijk JE, van den Bosch NH, Zorn I, Gabreëls-Festen AW, de Visser M, Bolhuis PA.

Nat Genet. 1992 Dec;2(4):288-91.

PMID:
1303281
31.

The peripheral myelin gene PMP-22/GAS-3 is duplicated in Charcot-Marie-Tooth disease type 1A.

Valentijn LJ, Bolhuis PA, Zorn I, Hoogendijk JE, van den Bosch N, Hensels GW, Stanton VP Jr, Housman DE, Fischbeck KH, Ross DA, et al.

Nat Genet. 1992 Jun;1(3):166-70.

PMID:
1303229
32.

De-novo mutation in hereditary motor and sensory neuropathy type I.

Hoogendijk JE, Hensels GW, Gabreëls-Festen AA, Gabreëls FJ, Janssen EA, de Jonghe P, Martin JJ, van Broeckhoven C, Valentijn LJ, Baas F, et al.

Lancet. 1992 May 2;339(8801):1081-2.

PMID:
1349106

Supplemental Content

Loading ...
Support Center